Biomarkers: Discovery Techniques and Applications - A Global Market Overview

NEW YORK, Nov. 14, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biomarkers: Discovery Techniques and Applications - A Global Market Overview

http://www.reportlinker.com/p0296476/Biomarkers-Discovery-Techniques-and-Applications---A-Global-Market-Overview.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

The potential offered by biomarkers in shaping the outcomes of clinical trials, identifying new drug targets and developing diagnostic assays for detecting diseases early is immense, which has ensued in a large number of scientific publications coming out over the past two decades. Biomarker research encompasses widespread fields of discipline, which comprise drug discovery, toxicity, clinical markers of efficacy and therapeutic indicators, development of diagnostic assays and environmental pollutant exposure. The fields of epidemiology and toxicology have also made use of biomarkers in indicating exposure to a range of environmental substances. In such instances, the biomarker could be the substance itself, such as asbestos particles or nicotine-derived nitrosamine ketone (NNK) from tobacco, or a variation of the external substance processed by the body, such as a metabolite. Using biomarkers in species, such as aquatic animals and invertebrates can be helpful in determining levels and ranges of environmental pollutants.

Personalized medicine constitutes another facet that has been in an ever increasing mode, wherein genomic data are utilized for classifying subsets of patients that would respond to a specific line of therapy. The progression of biomarker research in ascertaining the basics of personalized medicine implies that the prospects of jointly developing drugs and biomarkers would be associated with identifying that section of the population that would garner the maximum benefit from that drug treatment. Developing such biomarkers requires expending considerable efforts and resources, which would enable in expanding the tasks accomplished by biomarkers in disease screening as surrogate endpoints and diagnostic indices.

Biomarker discovery techniques analyzed in this report include Bioimaging, Bioinformatics and Omics Technologies. On a broader geographic level, these technologies further drilled down to Bioimaging – Computed Tomography (CT), Magnetic Resonence Imaging (MRI), Ultrasound and Other; and Omics Technologies – Genomics, Metabolomics, Proteomics and Other. The study also explores the global market for therapeutic areas of biomarkers comprising Cardiology, Neurology, Oncology and Other.

The report reviews, analyses and projects the Biomarkers market for global and the regional markets including the United States, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 10 independent countries across Europe – France, Germany, Italy, Spain, Sweden, the United Kingdom; and Asia-Pacific – Australia, China, India and Japan. Accounting for a lion's share of an estimated 47% in 2013, equating to US$18.9 billion, the United States leads the global market for Biomarkers. Growing at a robust compounded annual growth rate of 18.8% during the period 2013-2020, the global market is projected to touch US$63.2 billion.

This 350 pages, global market report includes 100 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the market value in US$ by geographic region, biomarker discovery techniques and therapeutic area. This report profiles 52 key global players and 70 major players across the United States – 34; Europe – 24; Asia-Pacific – 7 and Rest of World - 5. The research also provides the listing of the companies engaged in research & development, equipment manufacturing and supply of biomarkers. The global list of companies covers addresses, contact numbers and the website addresses of 245 companies.

TABLE OF CONTENTS:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

1.1.1 Biomarkers in Medicine

1.1.1.1 A History of Biomarkers

1.1.1.1.1 Philadelphia Chromosome

1.1.1.1.2 HIV Viral Load

1.1.1.1.3 HER-2 Gene and Receptor

1.1.1.2 Biomarkers for Diseases and Biomarkers for Drugs

1.1.1.3 Prerequisites of Biomarkers

1.1.1.4 Categorization of Biomarkers

1.1.1.4.1 Categorization of Biomarkers based on Types

1.1.1.5 Biomarkers in Drug Development

1.1.1.6 Biomarker in Diseases

1.1.2 Biomarker Discovery Technologies

1.1.2.1 Imaging-Based Biomarkers

1.1.2.1.1 Imaging Technologies

1.1.2.1.1.1 X-Rays

1.1.2.1.1.2 Computed Tomography (CT)

1.1.2.1.1.3 Positron Emission Tomography (PET)

1.1.2.1.1.4 Single Photon Emission Computed Tomography (SPECT)

1.1.2.1.1.5 Magnetic Resonance Imaging (MRI)

1.1.2.1.1.6 Ultrasound (US)

1.1.2.1.1.7 Others

1.1.2.2 Bioinformatics

1.1.2.3 Omics Technologies

1.1.2.3.1 Genomic Methods of Biomarker Discovery

1.1.2.3.2 Metabolomics Methods of Biomarker Discovery

1.1.2.3.3 Proteomic Methods of Biomarker Discovery

1.1.2.3.4 Other Omics Technologies for Biomarker Discovery

1.1.2.3.4.1 Lipidomics

1.1.2.3.4.2 Glycomics

1.1.2.3.4.3 Secretomics

1.1.3 Therapeutic Areas for Biomarkers

1.1.3.1 Cardiac Biomarkers

1.1.3.1.1 Measurement Applications of Cardiac Biomarkers

1.1.3.1.2 Classes of Cardiac Marker Tests

1.1.3.1.3 Biomarkers of Coronary Artery Disease

1.1.3.2 Neurological Disorder Biomarkers

1.1.3.3 Cancer Biomarkers

1.1.3.3.1 Cancer Biomarkers Defined

1.1.3.3.2 Functions of Biomarkers in Cancer Medicine

1.1.3.3.3 Functions of Biomarkers in Cancer Research

1.1.3.3.4 Categories of Cancer Markers

1.1.3.4 Other Therapeutic Areas for Biomarkers

1.1.3.4.1 Biomarkers of Diabetes

1.1.3.4.2 Biomarkers of Aging

2. KEY MARKET TRENDS

Detection of Cancer Biomarkers in Chemical Plume over Urine Samples Enabled by Mass SpectrometryIdentification of Early Stage Kidney Cancer Could be Facilitated through a Triumvirate of BiomarkersCancer Biomarker Detection Using Carbon-Nanotube SensorsDevelopment of Barrett's Esophagus to Esophageal Adenocarcinoma Predicted through Novel BiomarkersMetastatic Breast Cancer Detected by Circulating Tumor DNANew Biomarker for Bone Marrow Cancer IdentifiedDetecting Breast Cancer Early and Monitoring Therapy with Blood TestsIdentification of Neuroblastomas with Sensitivity to BET Bromodomain Inhibitors Enabled through BiomarkerEarlier Diagnosis of Parkinson's Disease Enabled through Blood-Based BiomarkersDetection of Gliomas to be Assisted with a New BiomarkerNew Biomarkers for Multiple SclerosisDeveloping Novel Therapies for Diabetes Facilitated with New BiomarkersTrends in Approval for IVDs Based on BiomarkersDeveloping Genomic Biomarkers Facilitated through Innovative Tissue SamplesProspects of Enabling Earlier Cancer Diagnosis Offered by Innovative TechnologyPossibilities for Cancer Therapy and Diagnosis Opened Up through MicroRNAsInnovative MRI Technique Assists in Diagnosing Dementia PatientsPreventive Molecular Medicine and Metabolic BiomarkersPredicting Cardiac Damage Induced Via Chemotherapy Earlier Facilitated by BiomarkersPromising Proteomic Techniques in Biomarker Research for Prostate Cancer BiomarkersTechnology Innovation for Identifying Ulcerative Colitis BiomarkersSuccess Rate of Clinical Trials of New Breast Cancer Drugs Enhanced with BiomarkersEye Movements as Biomarkers of SchizophreniaNew Biomarker Betters Prospects of Diagnosing Alzheimer's DiseaseIdentifying and Treating Schizophrenia with BiomarkersEarly Disease Detection Facilitated Via Ultra-Sensitive TestsResearch and Development Efforts in Biomarkers: Some Notable TrendsOral Cancer Detection Capacity Significantly Enhanced by Saliva TestAutism Biomarkers Discovered

3. KEY MAJOR PLAYERS

Abbott Laboratories, Inc.

ACE Biosciences A/S

Affibody AB

Affymetrix, Inc.

Agendia N.V.

Agilent Technologies, Inc.

Altheadx, Inc.

Amgen, Inc.

Analytical Biological Services Inc.

Astrazeneca Plc

Banyan Biomarkers Inc.

Bayer AG

Beckman Coulter, Inc.

Becton, Dickinson and Company

BG Medicine, Inc.

Biocartis SA

Biomérieux SA

Bio-Rad Laboratories, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Bruker Corporation

Celera Corporation

Charles River Laboratories International, Inc.

Clarient, Inc.

Compugen Ltd.

Decode Genetics

Dr. Reddy's Laboratories Limited

EMD Millipore Corporation

Epigenomics AG

F. Hoffmann-La Roche Ltd.

GE Healthcare Ltd.

Genedata AG

Glaxosmithkline, Plc

Johnson & Johnson

Merck & Co., Inc.

Nordion Inc.

Novartis AG

Perkinelmer Inc.

Pfizer, Inc.

Pharmaceutical Product Development, LLC.

Philips Healthcare

Ranbaxy Laboratories Limited

Roche Diagnostics Corporation

Rosetta Genomics Ltd.

Sanofi

Shimadzu Scientific Instruments, Inc

Siemens Healthcare

Siemens Healthcare Diagnostics, Inc.

Sigma-Aldrich Corporation

Takeda Pharmaceutical Company Limited

Thermo Fisher Scientific Inc

UCB S.A.

4. KEY BUSINESS TRENDS

Unveiling of NanoString's nCounter Elements™ General Purpose Reagents for Translational Research and Clinical LaboratoriesPhase I Trial for VAL201, ValiRx's Lead CompoundResearchers Identified Novel Blood Test for Alzheimer's disease DiagnosisCommercial Launch of Quanterix's Simoa TechnologyStrategic Alliance between Affymetrix and Massachusetts General Hospital for Oncology Biomarker ResearchMolecularMD Corp. Acquires DDR2 Biomarker Commercial RightsGEMMs Employed in the Development of Biomarkers for Molecular Subtypes DetectionC2N and Cambridge Isotope Laboratories Form Biomarkers Research and Supply PactResearchers Identified Advance Biomarkers to Detect AutismResearchers at Emory Conduct Clinical Diagnosis Trial for Early Detection of PDGenewiz and BeiGene Pair Up to Expedite the Discovery of Cancer BiomarkersCollaboration of Fluidigm and Olink Bioscience to Discover Novel Protein BiomarkersDaVita Labs, Myriad RBM Pair up for Protein Biomarkers DiscoveryResults from Novel Biomarker Analyses of Vectibix® plus FOLFOX in mCRC PatientsFDA Approves bioMérieux SA's new THxID-BRAF Molecular TestOxford Cancer Biomarkers and AstraZeneca form Biomarker Discovery PactAgilent Technologies Join Forces with Applied Proteomics for Broadening Highly Multiplexed Protein Assays' PotenciesOGT Acquired Rights for Advanced Development and Commercialization of microRNA Biomarkers for Prostate CancerKineMed Unveiled Kinetic Biomarkers for Neurological DisordersMerck Partners with Luminex on Companion Diagnostic Development for Alzheimer's DiseaseST2 Biomarker Detects High Dose Beta Blocker Therapy for Heart Failure ManagementEMD Millipore Broadens its Biomarker Testing Service CompetencesUnveiling of Horizon's First Quantitative Multiplex Genomic DNA Reference StandardAdvanced Cell Diagnostics, The Johns Hopkins University Pair up for New Cancer Immunotherapy Biomarkers and Drug Targets ValidationSengenics, Oxford Gene Technology Pair Up to Unveil Global Biomarker Discovery and Clinical Trial Immuno-Response Monitoring ServiceBiotie Therapies' tozadenant Receives Global License from UCBNovel Personalized Medicine Partnership for Cancer headed by CaprionLaunch of RNAscope SpotStudio™ Image Analysis Software by Definiens and ACDCollaboration between Covance and M2Gen® to Further Personalized Cancer TreatmentInitiation of Parkinson's disease Biomarkers Program by NINDS of NIHIssue of US Patent for Cardiac Troponin Biomarker Complex Detection of AxelaDiscovery of New Biomarker and IL-6 Targeted Therapy in MS by BRI ResearchersDaiichi Sankyo and Amplimmune Form Protein Development PactAddition of Novel Biomarkers Deepen QIAGEN's Personalized Healthcare Diagnostic PortfolioMerck Establishes Strategic Alliance with GE Healthcare to Employ [18F] Flutemetamol in AD DiagnosisNovel Genomic Biomarker Services Provided by EMD MilliporeRelease of Biocartis' DMAT Detection Platform for Biomarker AnalysisMyriad RBM Teamed Up with Sanofi and PHRI to Discover Protein Biomarkers for DiabetesAVEO and Astellas Started Enrolling Patients in BATON-BC Clinical StudyGE Healthcare Announces the Consequences of the Early Economic Evaluation StudiesMulti-year Collaboration between Thermo Fisher Scientific and Fujirebio Inc. to Commercialize PCT AssayRenewal of PCT Testing Collaboration between Thermo Fisher Scientific and bioMérieuxLaunch of Thermo Scientific Mass Spectrometric Immunoassay Pipette TipsEzose Sciences, Fast Forward Collaborate on MS Diagnostic Biomarkers DiscoveryAstraZeneca and Roche Diagnostics Pair Up for Advanced Companion DiagnosticsQuintiles Establishes Oxford Cancer Biomarkers to Develop Oncology BiomarkersAgilent Technologies and Gachon University Pair Up for Biomarkers DiscoveryCommercial Release of UCB's Neupro® in the US for PD and RLS treatmentAgilent Technologies, Gachon University Pair Up to Discover Oncology and Diabetes BiomarkersVTT Partners with GE Healthcare on Novel AD Biomarkers DiscoveryAgilent Technologies Plans to Establish Novel Neurometabolomics Research and Training Center in the City of DaeguBio-Rad Joined Forces with Myriad RBM on Multiplexed Immunoassay KitsNeviah Genomics Established by Merck Serono and CompugenAffymetrix and Massachusetts General Hospital Partner to Develop Biomarker Tests for CancerCommercial Launch of First Generation Animal Biomarker Assay from NextGen to Diagnose Brain DisordersUnveiling of Aushon's Cira™ Multiplex Immunoassay PlatformKineMed, GSK Pair up for Biomarker Research and DevelopmentCommercial Launch of Novel Diagnostic Biomarker Assay for Brain DisordersLicense Renewal of Genedata Expressionist® for Mass SpectrometryClarient, Insight Pair up to License ALK Gene Testing for Lung CancerGenomic Health Partners with OncoMed for NGS Diagnostic R&D based Biomarkers DiscoveryHistoRx Inc. Uses its Patented AQUA Technology to Evaluate mRNA in TissueAbbott Receives Selective Rights for Genetic Biomarkers to Predict Specific Prostrate CancerTakeda and Metabolon Form Drug Discovery PactCommercial Launch of Novel Assay to Identify Biomarkers in Human BloodMetabolon Establishes Alliance with Takeda on New Therapeutic Targets and Biomarkers ResearchSomaLogic and the University of Washington Published the First Application Report of the SOMAscan™ Proteomic Assay TechnologyEzose Sciences, Hirosaki University Pair up to Discover Novel Oncology BiomarkersAlmac Collaborated with Affymetrix for Global Market Distribution of its Xcel™ ArrayUnveiling of Bio-Rad's Novel Bio-Plex Pro™ immunoassays to Discover Human Th17 Cytokines and Cancer BiomarkersBristol-Myers Squibb Partners with Meso Scale Discovery on AD Diagnostics Assays DevelopmentFirst Commercial Mass Sequencing Laboratory of Chronix Biomedical InauguratedEpistem Joined Forces with Glaxosmithkline to Detect Fibrosis BiomarkersHTG Partners with Sanofi US on Biomarkers ResearchQIAGEN Broadens its Companion Diagnostics Portfolio by Receiving Genomic Biomarkers LicenseBruker and SISCAPA Assay Technologies Together Published a Paper on SISCAPA-MALDI-TOF Mass SpectrometryAgilent Technologies and Integrated Diagnostics Joined Forces on Proteomic Assays DevelopmentEMD Millipore and Proteomics International Partner to Validate Diabetic Nephropathy BiomarkersBiomnis, Trans-Hit Biomarkers Join Forces on Biomarker Research and CommercializationSanofi Establishes Alliance with Foundation Medicine to Detect Oncology Biomarkers and CDsResearch Collaboration between Ezose Sciences and Merck to Discover Biomarkers for DiabetesPacific Biomarkers Partnered with Clinigene International on Specialty Biomarker and High-end Clinical Laboratory ServicesApplication of GeneNews' Sentinel Principle® to Identify NPC Biomarkers9-miRNA Biomarkers for Enhanced Pancreatic Cyst Patients' StratificationExonhit and Pfizer Collaborates on Alzheimer's disease Biomarker ResearchUnveiling of Definiens' Novel Quantitative Digital Pathology Product SuiteResearch to Develop Novel Protein-based Technology at the Broad Institute Supported by AgilentDefiniens Plans to Launch Novel Generation of Products for Tissue-based Biomarker ResearchMerck and BGI Joined Forces for Biomarkers and Genomic Technologies Discovery and DevelopmentSuccessful Completion of Phase II multi-center Clinical Study by Siemens

5. GLOBAL MARKET OVERVIEW

5.1 Market Overview by Biomarker Discovery Technology

Bioimaging Market Overview by Imaging Modality

Omics Technology Market Overview by Segment

5.1.1 Biomarkers Discovery Technology Overview by Global Region

5.1.1.1 Bioimaging

5.1.1.2 Bioinformatics

5.1.1.3 Omics Technology

5.2 Market Overview by Biomarkers Therapeutic Area

5.2.1 Biomarkers Therapeutic Area Overview by Global Region

5.2.1.1 Cardiology

5.2.1.2 Neurology

5.2.1.3 Oncology

5.2.1.4 Other Disease Areas

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW 1. THE UNITED STATES

1.1 United States Biomarkers Market Overview by Discovery TechnologyUnited States Bioimaging Market Overview by Imaging ModalityUnited States Omics Technology Market Overview by Segment1.2 United States Market Overview by Biomarkers Therapeutic Area1.3 Major Market PlayersAbbott Laboratories, Inc. (United States)Affymetrix, Inc. (United States)Agilent Technologies, Inc. (United States)Altheadx, Inc. (United States)Amgen, Inc. (United States)Analytical Biological Services Inc. (United States)Applied Neurosolutions, Inc. (United States)Asuragen, Inc. (United States)Aviva Biosciences Corporation (United States)Banyan Biomarkers Inc. (United States)Beckman Coulter, Inc. (United States)Becton, Dickinson And Company (United States)BG Medicine, Inc. (United States)Bio-Rad Laboratories, Inc. (United States)Bristol-Myers Squibb Company (United States)Bruker Corporation (United States)Celera Corporation (United States)Charles River Laboratories International, Inc. (United States)Clarient, Inc. (United States)EMD Millipore Corporation (United States)Genentech, Inc. (United States)Genomic Health Inc. (United States)Johnson & Johnson (United States)Merck & Co., Inc. (United States)Metabolon, Inc. (United States)Myriad Genetics, Inc. (United States)Perkinelmer Inc. (United States)Pfizer, Inc. (United States)Pharmaceutical Product Development, LLC. (United States)Roche Diagnostics Corporation (United States)Shimadzu Scientific Instruments, Inc. (United States)Siemens Healthcare Diagnostics, Inc. (United States)Sigma-Aldrich Corporation (United States)Thermo Fisher Scientific Inc. (United States)

2. EUROPE

2.1 European Biomarkers Market Overview by Geographic Region

2.2 European Biomarkers Market Overview by Discovery Technology

European Bioimaging Market Overview by Imaging Modality

European Omics Technology Market Overview by Segment

2.2.1 Biomarkers Discovery Technology Overview by European Region

2.2.1.1 Bioimaging

2.2.1.2 Bioinformatics

2.2.1.3 Omics Technology

2.3 European Market Overview by Biomarkers Therapeutic Area

2.4 Major Market Players

ACE Biosciences A/S (Denmark)

Affibody AB (Sweden)

Agendia N.V. (Netherlands)

Alphalyse A/S (Denmark)

Ani Biotech Oy (Finland)

Astrazeneca Plc (United Kingdom)

Bayer AG (Germany)

Biocartis SA (Switzerland)

Biomérieux SA (France)

Biosystems International (France)

Boehringer Ingelheim Gmbh (Germany)

Dako Denmark A/S (Denmark)

Decode Genetics (Iceland)

Epigenomics AG (Germany)

F. Hoffmann-La Roche Ltd. (Switzerland)

GE Healthcare Ltd. (United Kingdom)

Genedata AG (Switzerland)

Glaxosmithkline, Plc (United Kingdom)

Novartis AG (Switzerland)

Pamgene International BV (Netherlands)

Philips Healthcare (Netherlands)

Sanofi (France)

Siemens Healthcare (Germany)

UCB S.A. (Belgium)

2.5 European Biomarkers Market Overview by Country2.5.1 France2.5.2 Germany2.5.3 Italy2.5.4 Spain2.5.5 Sweden2.5.6 The United Kingdom2.5.7 Rest of Europe

3. ASIA-PACIFIC

3.1 Asia-Pacific Biomarkers Market Overview by Geographic Region

3.2 Asia-Pacific Biomarkers Market Overview by Discovery Technology

Asia-Pacific Bioimaging Market Overview by Imaging Modality

Asia-Pacific Omics Technology Market Overview by Segment

3.2.1 Biomarkers Discovery Technology Overview by Asia-Pacific Region

3.2.1.1 Bioimaging

3.2.1.2 Bioinformatics

3.2.1.3 Omics Technology

3.3 Asia-Pacific Market Overview by Biomarkers Therapeutic Area

3.4 Major Market Players

Astellas Pharma Inc. (Japan)

Dr. Reddy's Laboratories Limited (India)

GVK Biosciences Private Limited (India)

Human Metabolome Technologies Inc. (Japan)

Ocimum Biosolutions Ltd. (India)

Ranbaxy Laboratories Limited (India)

Takeda Pharmaceutical Company Limited (Japan)

3.5 Asia-Pacific Biomarkers Market Overview by Country3.5.1 Australia3.5.2 China3.5.3 India3.5.4 Japan3.5.5 Rest of Asia-Pacific

4. REST OF WORLD

4.1 Rest of World Biomarkers Market Overview by Discovery Technology

Rest of World Bioimaging Market Overview by Imaging Modality

Rest of World Omics Technology Market Overview by Segment

4.2 Rest of World Market Overview by Biomarkers Therapeutic Area

4.3 Major Market Players

Compugen Ltd. (Israel)

Diagnocure Inc. (Canada)

Miraculins Inc. (Canada)

Nordion Inc. (Canada)

Rosetta Genomics Ltd. (Israel)

PART C: GUIDE TO THE INDUSTRY

1. NORTH AMERICA Canada

1.2 United States

2. EUROPE

2.1 Belgium2.2 Denmark2.3 Finland2.4 France2.5 Germany2.6 Iceland2.7 Ireland2.8 Italy2.9 Norway2.10 Spain2.11 Sweden2.12 Switzerland2.13 The Netherlands2.14 United Kingdom

3. ASIA-PACIFIC

3.1 Australia

3.2 China

3.3 India

3.4 Japan

3.5 Malaysia

4. REST OF WORLD

4.1 Israel

PART D: ANNEXURE

1. RESEARCH METHODOLOGY2. FEEDBACK

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVE

Chart 1: Trending of Global Market for Biomarker Identification by Omics Technology – Genomics, Metabolomics, Proteomics and Others in USD MillionChart 2: Trending of Global Market for Biomarker Identification by Bioimaging Modality – CT, MRI, Ultrasound, and Others in USD MillionChart 3: Global Biomarkers Market Analysis (2010-2020) in US$ MillionChart 4: Global Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ MillionChart 5: Glance at 2010, 2015 and 2020 Global Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics TechnologiesChart 6: Global Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Imaging Modality – CT, MRI, Ultrasound and Other in US$ MillionChart 7: Glance at 2010, 2015 and 2020 Global Bioimaging for Biomarker Discovery Market Share (%) by Imaging Modality – CT, MRI, Ultrasound and Other TechnologiesChart 8: Global Omics Technologies for Biomarker Discovery Market Analysis (2010-2020) by Segment – Genomics, Metabolomics, Proteomics and Other in US$ MillionChart 9: Glance at 2010, 2015 and 2020 Global Omics Technologies for Biomarker Discovery Market Share (%) by Segment – Genomics, Metabolomics, Proteomics and OtherChart 10: Global Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ MillionChart 11: Glance at 2010, 2015 and 2020 Global Bioimaging for Biomarkers Discovery Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 12: Global Bioinformatics for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ MillionChart 13: Glance at 2010, 2015 and 2020 Global Bioinformatics for Biomarkers Discovery Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 14: Global Omics Technologies for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ MillionChart 15: Glance at 2010, 2015 and 2020 Global Omics Technology for Biomarkers Discovery Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 16: Global Biomarkers Market Analysis (2010-2020) by Therapeutic Area – Cardiology, Neurology, Oncology and Other in US$ MillionChart 17: Glance at 2010, 2015 and 2020 Global Biomarkers Market Share (%) by Therapeutic Area – Cardiology, Neurology, Oncology and OtherChart 18: Global Biomarkers Market Analysis (2010-2020) in Cardiology by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ MillionChart 19: Glance at 2010, 2015 and 2020 Global Cardiology Market Share (%) of Biomarkers by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 20: Global Biomarkers Market Analysis (2010-2020) in Neurology by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ MillionChart 21: Glance at 2010, 2015 and 2020 Global Neurology Market Share (%) of Biomarkers by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 22: Global Biomarkers Market Analysis (2010-2020) in Oncology by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ MillionChart 23: Glance at 2010, 2015 and 2020 Global Oncology Market Share (%) of Biomarkers by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 24: Global Biomarkers Market Analysis (2010-2020) in Other Disease Areas by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ MillionChart 25: Glance at 2010, 2015 and 2020 Global Other Disease Areas Market Share (%) of Biomarkers by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

Chart 26: Projection of Prospective Regions in terms of Market Growth (CAGR) between 2010 and 2020 for Biomarkers by Geographic Region – Asia-Pacific, Europe and United StatesChart 27: Global Biomarkers Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ MillionChart 28: Glance at 2010, 2015 and 2020 Global Biomarkers Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

THE UNITED STATES

Chart 29: United States Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million

Chart 30: Glance at 2010, 2015 and 2020 United States Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Chart 31: United States Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Imaging Modality – CT, MRI, Ultrasound and Other in US$ Million

Chart 32: Glance at 2010, 2015 and 2020 United States Bioimaging for Biomarker Discovery Market Share (%) by Imaging Modality – CT, MRI, Ultrasound and Other Technologies

Chart 33: United States Omics Technology for Biomarker Discovery Market Analysis (2010-2020) by Segment – Genomics, Metabolomics, Proteomics and Other in US$ Million

Chart 34: Glance at 2010, 2015 and 2020 United States Omics Technology for Biomarker Discovery Market Share (%) by Segment – Genomics, Metabolomics, Proteomics and Other

Chart 35: United States Biomarkers Market Analysis (2010-2020) by Therapeutic Area – Cardiology, Neurology, Oncology and Other in US$ Million

Chart 36: Glance at 2010, 2015 and 2020 United States Biomarkers Market Share (%) by Therapeutic Area – Cardiology, Neurology, Oncology and Other

EUROPE

Chart 37: European Biomarkers Market Analysis (2010-2020) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of Europe in US$ MillionChart 38: Glance at 2010, 2015 and 2020 European Biomarkers Market Share (%) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of EuropeChart 39: European Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ MillionChart 40: Glance at 2010, 2015 and 2020 European Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics TechnologiesChart 41: European Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Imaging Modality – CT, MRI, Ultrasound and Other in US$ MillionChart 42: Glance at 2010, 2015 and 2020 European Bioimaging for Biomarker Discovery Market Share (%) by Imaging Modality – CT, MRI, Ultrasound and Other TechnologiesChart 43: European Omics Technology for Biomarker Discovery Market Analysis (2010-2020) by Segment – Genomics, Metabolomics, Proteomics and Other in US$ MillionChart 44: Glance at 2010, 2015 and 2020 European Omics Technology for Biomarker Discovery Market Share (%) by Segment – Genomics, Metabolomics, Proteomics and OtherChart 45: European Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of Europe in US$ MillionChart 46: Glance at 2010, 2015 and 2020 European Bioimaging for Biomarkers Discovery Market Share (%) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of EuropeChart 47: European Bioinformatics for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of Europe in US$ MillionChart 48: Glance at 2010, 2015 and 2020 European Bioinformatics for Biomarkers Discovery Market Share (%) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of EuropeChart 49: European Omics Technology for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – France, Germany, Italy, Spain, Sweden, United Kingdom and Rest of Europe in US$ MillionChart 50: Glance at 2010, 2015 and 2020 European Omics Technology for Biomarkers Discovery Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of WorldChart 51: European Biomarkers Market Analysis (2010-2020) by Therapeutic Area – Cardiology, Neurology, Oncology and Other in US$ MillionChart 52: Glance at 2010, 2015 and 2020 European Biomarkers Market Share (%) by Therapeutic Area – Cardiology, Neurology, Oncology and Other

France

Chart 53: French Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million

Chart 54: Glance at 2010, 2015 and 2020 French Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

GermanyChart 55: German Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ MillionChart 56: Glance at 2010, 2015 and 2020 German Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Italy

Chart 57: Italian Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million

Chart 58: Glance at 2010, 2015 and 2020 Italian Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

SpainChart 59: Spanish Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ MillionChart 60: Glance at 2010, 2015 and 2020 Spanish Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Sweden

Chart 61: Swedish Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million

Chart 62: Glance at 2010, 2015 and 2020 Swedish Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

The United KingdomChart 63: United Kingdom Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ MillionChart 64: Glance at 2010, 2015 and 2020 United Kingdom Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Rest of Europe

Chart 65: Rest of Europe Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million

Chart 66: Glance at 2010, 2015 and 2020 Rest of Europe Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

ASIA-PACIFIC

Chart 67: Asia-Pacific Biomarkers Market Analysis (2010-2020) by Geographic Region – Australia, China, India, Japan and Rest of Asia-Pacific in US$ MillionChart 68: Glance at 2010, 2015 and 2020 Asia-Pacific Biomarkers Market Share (%) by Geographic Region – Australia, China, India, Japan and Rest of Asia-PacificChart 69: Asia-Pacific Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ MillionChart 70: Glance at 2010, 2015 and 2020 Asia-Pacific Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics TechnologiesChart 71: Asia-Pacific Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Imaging Modality – CT, MRI, Ultrasound and Other in US$ MillionChart 72: Glance at 2010, 2015 and 2020 Asia-Pacific Bioimaging for Biomarker Discovery Market Share (%) by Imaging Modality – CT, MRI, Ultrasound and Other TechnologiesChart 73: Asia-Pacific Omics Technology for Biomarker Discovery Market Analysis (2010-2020) by Segment – Genomics, Metabolomics, Proteomics and Other in US$ MillionChart 74: Glance at 2010, 2015 and 2020 Asia-Pacific Omics Technology for Biomarker Discovery Market Share (%) by Segment – Genomics, Metabolomics, Proteomics and OtherChart 75: Asia-Pacific Bioimaging for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – Australia, China, India, Japan and Rest of Asia-Pacific in US$ MillionChart 76: Glance at 2010, 2015 and 2020 Asia-Pacific Bioimaging for Biomarkers Discovery Market Share (%) by Geographic Region – Australia, China, India, Japan and Rest of Asia-PacificChart 77: Asia-Pacific Bioinformatics for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – Australia, China, India, Japan and Rest of Asia-Pacific in US$ MillionChart 78: Glance at 2010, 2015 and 2020 Asia-Pacific Bioinformatics for Biomarkers Discovery Market Share (%) by Geographic Region – Australia, China, India, Japan and Rest of Asia-PacificChart 79: Asia-Pacific Omics Technology for Biomarker Discovery Market Analysis (2010-2020) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in US$ MillionChart 80: Glance at 2010, 2015 and 2020 Asia-Pacific Omics Technology for Biomarkers Discovery Market Share (%) by Geographic Region – Australia, China, India, Japan and Rest of Asia-PacificChart 81: Asia-Pacific Biomarkers Market Analysis (2010-2020) by Therapeutic Area – Cardiology, Neurology, Oncology and Other in US$ MillionChart 82: Glance at 2010, 2015 and 2020 Asia-Pacific Biomarkers Market Share (%) by Therapeutic Area – Cardiology, Neurology, Oncology and Other

Australia

Chart 83: Australian Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million

Chart 84: Glance at 2010, 2015 and 2020 Australian Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

ChinaChart 85: Chinese Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ MillionChart 86: Glance at 2010, 2015 and 2020 Chinese Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

India

Chart 87: Indian Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million

Chart 88: Glance at 2010, 2015 and 2020 Indian Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

JapanChart 89: Japanese Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ MillionChart 90: Glance at 2010, 2015 and 2020 Japanese Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies

Rest of Asia-Pacific

Chart 91: Rest of Asia-Pacific Biomarkers Market Analysis (2010-2020) by Discovery Technology – Bioimaging, Bioinformatics and Omics Technologies in US$ Million

Chart 92: Glance at 2010, 2015 and 2020 Rest of Asia-Pacific Biomarkers Market Share (%) by Discovery Technology – Bioimaging, Bioinformatics and Omic

To order this report: Biomarkers: Discovery Techniques and Applications - A Global Market Overview http://www.reportlinker.com/p0296476/Biomarkers-Discovery-Techniques-and-Applications---A-Global-Market-Overview.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker